AnaptysBio Inc Dossier - Source-backed chat

AnaptysBio Inc

ANABNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.61

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $50.26Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $1.5B

Enterprise Value $1.5B

Shares Outstanding 26.8M diluted

Moat Rating Wide

Next Earnings Date3 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

AnaptysBio has successfully transformed into a high-margin, pure-play royalty management company following the spin-off of its biopharma operations (First Tracks Biotherapeutics) in April 2026. By shedding its high-burn clinical pipeline, the company has dramatically lowered its capital intensity and operating expenses. The investment thesis centers on the rapid commercial uptake of GSK's Jemperli, which is on a ~$1.4 billion annualized run rate and is projected to deliver over $390 million in peak annual royalties to AnaptysBio by 2029. Additionally, the upcoming PDUFA date for imsidolimab (licensed to Vanda) on December 12, 2026, provides a near-term regulatory catalyst. While historical litigation with GSK remains an overhang, the streamlined corporate structure and a $100 million stock repurchase program offer a highly favorable risk-reward profile for value-oriented biotech investors.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets11 analysts · as of 18 Aug 2026

Low · most bearish analyst$70.00

Mean target$87.09

High · most bullish analyst$140.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

Jemperli sales growth slows due to competitive pressures or safety concerns, delaying the paydown of the Sagard monetization liability beyond Q2 2027. The Delaware Chancery Court rules unfavorably in the GSK/Tesaro litigation, impacting future royalty terms. Imsidolimab faces regulatory delays or a complete response letter (CRL) from the FDA on its December 2026 PDUFA date, and Vanda's commercial launch is weak.

Base CaseCentral scenario

GSK's Jemperli continues its strong commercial trajectory in endometrial cancer and successfully expands into broader solid tumor indications (such as dMMR rectal and colon cancers), driving steady royalty growth. The Sagard royalty monetization debt is fully paid off by mid-2027, allowing direct cash flows to accrue to AnaptysBio. Imsidolimab receives FDA approval in late 2026, triggering milestone payments and establishing a secondary 10% royalty stream from Vanda. The company executes its $100 million share buyback program, supporting the stock price.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Transition to a low-cost, high-margin royalty model with minimal operating expenses and limited FTE requirements.
Robust royalty stream from GSK's Jemperli, which grew 44% year-over-year to $24.7 million in Q1 2026.
Near-term regulatory catalyst with imsidolimab's PDUFA date set for December 12, 2026.
Strong balance sheet with $286.5 million in cash, cash equivalents, and investments as of March 31, 2026.
Active capital return program supported by a board-authorized $100 million stock repurchase plan.

Key Investment Risks

Ongoing high-stakes litigation with GSK/Tesaro in the Delaware Chancery Court.
Royalty cash flows are currently diverted to pay down the Sagard monetization liability (expected paydown by Q2 2027).
Concentration risk, as the company's valuation is heavily dependent on a single asset (Jemperli).
Potential volatility and reporting confusion during the transition to a June 30 fiscal year-end.

Thesis Invalidation Triggers

A major negative ruling in the GSK/Tesaro litigation that reduces Jemperli royalty rates or terminates the collaboration.
A significant slowdown in Jemperli commercial sales, pushing the Sagard paydown timeline past 2028.
FDA rejection (CRL) of imsidolimab on its December 12, 2026 PDUFA date.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.